文献速递皮肤感染皮肤肿瘤性传播疾病

HPV疫苗作为HPV相关异型增生和肿瘤性病变的治疗手段:文献综述

The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review.
PubMed 文献 · J Am Acad Dermatol · 2019-05-11

本综述遵循PRISMA指南检索PubMed和Cochrane数据库,纳入63篇文献共4439例患者,评估HPV疫苗作为皮肤和/或黏膜疾病治疗手段的效果。多数皮肤疣、复发性呼吸道乳头瘤病及鳞状和基底细胞癌患者经HPV疫苗接种后获得成功治疗;对已有肛门生殖器疣、宫颈上皮内瘤变、肛门上皮内瘤变和外阴上皮内瘤变的初步数据令人鼓舞。

要点

  • 市售三剂四价HPV疫苗是皮肤疣、复发性呼吸道乳头瘤病及鳞状和基底细胞癌的潜在治疗选择。
  • 非市售HPV疫苗对肛门生殖器疣、宫颈上皮内瘤变、肛门上皮内瘤变和外阴上皮内瘤变显示治疗反应。
  • HPV疫苗作为HPV相关皮肤和/或黏膜疾病辅助治疗的疗效值得进一步探索。

核心结论

  • 市售三剂四价HPV疫苗是皮肤疣、复发性呼吸道乳头瘤病及鳞状和基底细胞癌的潜在治疗选择。
  • 非市售HPV疫苗对肛门生殖器疣、宫颈上皮内瘤变、肛门上皮内瘤变和外阴上皮内瘤变显示治疗反应。
  • HPV疫苗作为HPV相关皮肤和/或黏膜疾病辅助治疗的疗效值得进一步探索。

研究设计与样本

  • 本综述为文献综述,遵循PRISMA指南于2019年1月在PubMed和Cochrane数据库进行原始文献检索。
  • 共纳入63篇文献,涉及4439例患者。

主要发现

  • 多数皮肤疣、复发性呼吸道乳头瘤病及鳞状和基底细胞癌患者经HPV疫苗接种后获得成功治疗。
  • 对已有肛门生殖器疣、宫颈上皮内瘤变、肛门上皮内瘤变和外阴上皮内瘤变患者的初步数据令人鼓舞。

临床怎么用

  • 对于皮肤疣、复发性呼吸道乳头瘤病及鳞状和基底细胞癌,可考虑HPV疫苗接种作为潜在治疗选择。
  • 对于肛门生殖器疣、宫颈上皮内瘤变、肛门上皮内瘤变和外阴上皮内瘤变,非市售HPV疫苗显示治疗反应,但需进一步验证。

局限性

  • 本综述缺乏对照。
  • 未充分控制患者既往HPV疫苗接种状态。
  • 存在发表偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Human papillomavirus (HPV) infections are associated with common dermatologic and nondermatologic diseases. Although HPV vaccines are well established as preventive measures for genital warts and cervical neoplasia, their use as therapeutic agents deserves greater attention. OBJECTIVE: To evaluate the use of HPV vaccine(s) as a treatment modality for cutaneous and/or mucosal disease. METHODS: A primary literature search using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was conducted in January 2019 by using the PubMed and Cochrane databases. RESULTS: A total of 63 articles with 4439 patients were included. The majority of patients with cutaneous warts, recurrent respiratory papillomatosis, and squamous and basal cell carcinomas were successfully treated with HPV vaccination. Preliminary data on patients with pre-existing anogenital warts, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia is promising. LIMITATIONS: This review was limited by the lack of controls, patients' previous HPV vaccination status, and publication bias. CONCLUSION: The commercially available three-dose, quadrivalent HPV vaccine is a potential therapeutic option for the treatment of cutaneous warts, recurrent respiratory papillomatosis, and squamous and basal cell carcinomas. Noncommercially available HPV vaccines demonstrate therapeutic response for treating anogenital warts, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia. The vaccine's efficacy as an adjunct therapy for HPV-associated cutaneous and/or mucosal disease warrants further exploration.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Pham CT, Juhasz M, Sung CT, et al. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review. J Am Acad Dermatol. 2019. PMID: 31085272. doi:10.1016/j.jaad.2019.04.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。